CAS No.:439-14-5

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	parenteral	> 800mg/kg (800mg/kg)		Drugs in Japan Vol. -, Pg. 500, 1995.
infant	TDLo	intravenous	150ug/kg (0.15mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	British Medical Journal. Vol. 2, Pg. 298, 1977.
mammal (species unspecified)	LD50	oral	500mg/kg (500mg/kg)		Doklady Akademii Nauk SSSR. Proceedings of the Academy of Sciences of the USSR. For English translation, see DBIOAM and DKBSAS. Vol. 320, Pg. 242, 1991.
mammal (species unspecified)	LD50	unreported	110mg/kg (110mg/kg)		Pharmaceutical Chemistry Journal Vol. 25, Pg. 193, 1991.
man	TDLo	intravenous	71ug/kg/1M-C (0.071mg/kg)	VASCULAR: OTHER CHANGES	Drug Intelligence and Clinical Pharmacy. Vol. 17, Pg. 125, 1983.
man	TDLo	intravenous	143ug/kg (0.143mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	JAMA, Journal of the American Medical Association. Vol. 238, Pg. 1052, 1977.
man	TDLo	oral	143ug/kg (0.143mg/kg)	SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: DIPLOPIA: EYE	British Journal of Clinical Pharmacology. Vol. 1, Pg. 335, 1974.
mouse	LD50	intramuscular	65mg/kg (65mg/kg)		European Journal of Pharmacology. Vol. 13, Pg. 150, 1971.
mouse	LD50	intraperitoneal	37mg/kg (37mg/kg)		Strahlentherapie. Vol. 127, Pg. 245, 1965.
mouse	LD50	intravenous	25mg/kg (25mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 31, Pg. 2180, 1981.
mouse	LD50	oral	48mg/kg (48mg/kg)		Pharmaceutical Chemistry Journal Vol. 17, Pg. 30, 1983.
mouse	LD50	parenteral	80mg/kg (80mg/kg)		United States Patent Document. Vol. #4371536,
mouse	LD50	rectal	500mg/kg (500mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 34, Pg. 2226, 1992.
mouse	LD50	skin	800mg/kg (800mg/kg)		Anesteziologiya i Reanimatologiya. Vol. (4), Pg. 57, 1980.
mouse	LD50	subcutaneous	800mg/kg (800mg/kg)		United States Patent Document. Vol. #3966793,
mouse	LD50	unreported	140mg/kg (140mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Pharmaceutical Chemistry Journal Vol. 18, Pg. 266, 1984.
rabbit	LD50	intravenous	9mg/kg (9mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: REGIDITY BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	International Journal of Neuropharmacology. Vol. 5, Pg. 305, 1966.
rabbit	LD50	oral	328mg/kg (328mg/kg)		Current Therapeutic Research, Clinical & Experimental. Vol. 7, Pg. 590, 1965.
rat	LD50	intraperitoneal	46500ug/kg (46.5mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
rat	LD50	intravenous	32mg/kg (32mg/kg)		Current Therapeutic Research, Clinical & Experimental. Vol. 7, Pg. 590, 1965.
rat	LD50	oral	249mg/kg (249mg/kg)		Drugs in Japan Vol. -, Pg. 500, 1995.
rat	LD50	parenteral	131mg/kg (131mg/kg)		Drugs in Japan Vol. -, Pg. 500, 1995.
rat	LD50	rectal	600mg/kg (600mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 34, Pg. 2226, 1992.
rat	LD50	subcutaneous	6350ug/kg (6.35mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992.
women	TDLo	intramuscular	181ug/kg (0.181mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) CARDIAC: CHANGE IN RATE	British Medical Journal. Vol. 1, Pg. 144, 1977.
women	TDLo	oral	5mg/kg (5mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	British Journal of Obstetrics and Gynaecology. Vol. 100, Pg. 185, 1993.

Consensus Reports：

Diazapam is reported in EPA TSCA Inventory. EPA Genetic Toxicology Program.

SAFETY PROFILE：

Hazard Codes: Xn,Xi,T,F 
Risk Statements: 21/22-39/23/24/25-23/24/25-11-36/37/38
R21/22:  Harmful in contact with skin and if swallowed 
R39/23/24/25:  Toxic: danger of very serious irreversible effects through inhalation, in contact with skin and if swallowed 
R23/24/25:  Toxic by inhalation, in contact with skin and if swallowed 
R11:  Highly Flammable 
R36/37/38:  Irritating to eyes, respiratory system and skin
Safety Statements: 36/37-45-36-26
S36/37:  Wear suitable protective clothing and gloves 
S45:  In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) 
S36:  Wear suitable protective clothing 
S26:  In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
RIDADR:  UN 2811 6.1/PG 3
WGK Germany:  2
RTECS: DF1575000
HazardClass: 6.1(b)
PackingGroup: III
Poison by ingestion, parenteral, subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by skin contact.  Human reproductive effects by ingestion and intravenous routes causing developmental abnormalities of the fetal cardiovascular (circulatory) system and postnatal effects. Experimental teratogenic and reproductive effects. Human mutation data reported. An allergen. A drug for the treatment of anxiety. When heated to decomposition it emits very toxic fumes of Cl⁻ and NO_x.

Standards and Recommendations：

 

Analytical Methods：